Vincent Rajkumar Profile picture
May 22, 2021 19 tweets 7 min read Read on X
Why are prescription drug prices so high in the US?

Let us start with insulin as an example. Insulin is the Achilles heel. If we understand insulin, we understand why it's so hard to fix our broken system.

1/ Existence of a vulnerable population needing a lifesaving medicine
2/ Monopoly

3 companies control the market for insulin. In a monopoly with significant regulatory and legal barriers to entry of competing products, the seller can set the price however high they want.

Here, the monopoly is not over a luxury item, but a lifesaving medicine.
3/ Patent Evergreening:
Making patent life extremely long & preventing competition.

Covert: By making newer version of a drug and patenting it (see insulin below)

Overt: Filing multiple new patents on same drug to stretch patent life, pay for delay schemes, lawsuits.
4/ Planned Obsolescence

When Pharma introduces new drugs, the new one is marketed as so much better, that using an older drug is not good clinical practice.

With insulin it's ok. But in other fields, new "me-too" drugs often provide minimal incremental value to justify cost.
5/ Biosimilar and Generic drug approval process is slow, expensive, and complicated. Numerous regulatory and legal barriers.

Studies show you need 4 or more competing biosimilars/generics to have an effect on price. One is not enough.
6/ Price "Collusion"

Absent true completion, if just 2 companies make similar products they can choose to increase prices in lock step. Both benefit. With insulin for years prices of competing drugs increased almost on same day to same level. It is not overt collusion. But...
7/ The Middlemen

Everyone in the supply chain from Pharma to Wholesaler to Pharmacy Benefit Manager to Pharmacy benefits from a higher price, except the patient. Profit is proportional to list price, which means it's in everyone's interest to have a high price.
8/ Influence of the Pharma Lobby

Pharmaceutical companies spend a lot on lobbying. Which is why nothing ever gets done.

Plus the factors for high price (#1-7) are many, and it's easy to point fingers.
9/ There are also other factors that make prices insanely high that are unique to the US:

Medicare must buy, but cannot negotiate.

Prescribers of meds administered in doctors offices stand to gain more by prescribing a more expensive option.
10/ So what are the solutions?

Every western nation has value based pricing. A maximum price that is negotiated for new drugs proportional to the value they provide. This ensures a reasonable launch price, & prevents the type of crazy price increases that are possible in the US
11/ Medicare must be able to negotiate for prices.

@ASlavitt once said almost 90% of Americans agree that Medicare should negotiate for drug prices, and 90% of Americans agree on very few things!
12/ Reform regulatory and patent process to make it easier for generics and biosimilars to end the market.

We cannot allow patent evergreening by repeated new patents filed on the same drugs as is the case with analog insulins and many new drugs.
13/ Eliminate reimbursement for drugs administered in doctors offices from a % of sales price to a fixed reimbursement. The current system encourages the use of a more expensive alternative when an equivalent cheaper one is available.
14/ Reforms to ensure that price increases are not related to rebates and lack of transparency in deals between Pharma and PBMs.

Many ways to do this. Including transparency, ending practice of rebates or passing rebates to patients. There will be many trade offs. It's complex.
15/ What can individual doctors do?

Help patients find the lowest cost options. Always prefer generics and biosimilars if possible.

For patients paying cash, prices of common drugs can vary dramatically. @GoodRx helps find the lowest price.
16/ Talk to patients about cost and affordability. Take cost and cost effectiveness into account when prescribing.
17/ I have discussed this in detail in a talk I gave @MayoClinic and you can access it here if interested. The problem of prescription drug prices is complex and unless we recognize the myriad factors and how they interact it is hard to fix.
cc: @hasanminhaj -- You have spoken about many of these issues on Patriot Act
My article on insulin pricing and what we can do about it. @MayoProceedings mayoclinicproceedings.org/article/S0025-…

• • •

Missing some Tweet in this thread? You can try to force a refresh
 

Keep Current with Vincent Rajkumar

Vincent Rajkumar Profile picture

Stay in touch and get notified when new unrolls are available from this author!

Read all threads

This Thread may be Removed Anytime!

PDF

Twitter may remove this content at anytime! Save it as PDF for later use!

Try unrolling a thread yourself!

how to unroll video
  1. Follow @ThreadReaderApp to mention us!

  2. From a Twitter thread mention us with a keyword "unroll"
@threadreaderapp unroll

Practice here first or read more on our help page!

More from @VincentRK

Jun 25
Cure is a simple word. But there is confusion when it comes to cancer. What cure is in cancer, and what we should aspire for?

When can we say that a given type of cancer is curable?
Thread
1/
There is a difference between when we can say a particular cancer is a curable type versus whether individual patients with a given cancer can be considered potentially cured.

They are not the same.
2/
To call a cancer curable we must be able to treat the cancer for a finite duration, stop all therapy, and know that a certain % of patients will never relapse

Early stage solid tumors, Hodgkin lymphoma, DLBCL, ALL, AML are curable. Real cure. The definition of curable cancer
3/
Read 13 tweets
Jun 1
The 4 big myeloma randomized trials to watch out for @ASCO #ASCO24

1. Isa-VRd vs Isa-Rd newly diagnosed
2.Isa-VRd vs VRd (IMROZ)
3.DREAMM8 Bela-Pd vs Pd
4.Ven Dex vs Pom Dex (Canova)

See thread for why they are important.
1) The Triplet vs Quad trials with will define role of quads in elderly patients with newly diagnosed myeloma. They also provide frontline phase III data with Isatuximab— and a choice between Dara and Isa. For some patients Isa will be more cost effective. @Myeloma_Doc #ASCO24
2) Belantamab will make a comeback.

Corneal toxicity is low with reduced frequency dosing. The drug works very well. And in many patients with refractory myeloma belantamab may be safer and easier to do than bispecifics. We need options. #ASCO24
Read 12 tweets
May 31
Just out: Updated mSMART recommendations for treatment of relapsed refractory myeloma. #MedTwitter @MayoMyeloma

1/ CART is now included as an option for second or higher relapse. msmart.org/mm-treatment-g…
2/ Even though CART (cilta-cel) is approved for first relapse we are NOT including it in our main algorithm. Reserved only for special circumstances in this population. We have a long track record with standard triplets, and we are concerned about CART side effects. Image
3/ The current approach for second or higher relapse continues to define 3 specific types of Triple Class refractory. This makes it easier for clinicians to consider options. Image
Read 6 tweets
Apr 23
To my followers who wonder what MOC is, and why many doctors are tweeting about it. Thread.

1) Maintenance of Certification (MOC) is a redundant requirement thrust on US physicians by a private organization. We resent it.
2) MOC is causing frustration and burnout. Over the years, ABIM certification and MOC have become entrenched and institutions and insurers require it and will not accept any other alternative.

I am advocating on behalf of my colleagues in the US for change. To end MOC.
3) MOC requires us to pay fees imposed on us by a private organization and take multiple choice question tests irrelevant to our practice.
Read 8 tweets
Apr 17
10 suggested action items for physician colleagues suffering under the burden of @ABIMcert MOC. #MedTwitter

1. If your institution allows it, stop participating in MOC. Personally, MOC has no value to me.
2. If your institution requires ABIM certification, advocate for @InfoNbpas as alternative option.
3. Do not participate in more than one ABIM MOC specialty, the one that’s required by your institution. Save your money. Don’t spend a penny more than you have to.
Read 15 tweets
Apr 12
I see a lot of wrong analysis on accelerated approval and surrogate endpoints.

It’s always easy to criticize from the outside. The criticisms raised are well known to the FDA and investigators. They are considered. We go in eyes fully open. We try to do what’s best for patients
Without accelerated approval using surrogate endpoint of overall response rate in single arm trials, for 2-3 years lives would have been lost waiting for drugs like Velcade, Revlimid, pomalidomide, Daratumumab, carfilzomib and more.

My defense of accelerated approval in MM.
What kind of benefit are we talking about? How many years of life gained from accelerated approval pathway in MM?
Read 5 tweets

Did Thread Reader help you today?

Support us! We are indie developers!


This site is made by just two indie developers on a laptop doing marketing, support and development! Read more about the story.

Become a Premium Member ($3/month or $30/year) and get exclusive features!

Become Premium

Don't want to be a Premium member but still want to support us?

Make a small donation by buying us coffee ($5) or help with server cost ($10)

Donate via Paypal

Or Donate anonymously using crypto!

Ethereum

0xfe58350B80634f60Fa6Dc149a72b4DFbc17D341E copy

Bitcoin

3ATGMxNzCUFzxpMCHL5sWSt4DVtS8UqXpi copy

Thank you for your support!

Follow Us!

:(